Menu Search
Equities

CV Sciences Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0HRT:LSE

CV Sciences Inc

Actions
  • Price (USD)0.0395
  • Today's Change0.040 / --
  • Shares traded5.14k
  • 1 Year change--
  • Beta0.2898
Data delayed at least 20 minutes, as of Feb 06 2026 16:43 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company develops, manufactures, markets and sells herbal supplements, CBD products and plant-based food products under +PlusCBD, +PlusHLTH, Cultured Foods, and Lunar Fox brands in the healthcare market sector, including nutraceutical, beauty care, specialty foods, and pet products. Its hemp extracts, and other science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business (B2B) to business-to-consumer (B2C). Its +PlusCBD line of products are available in softgels, tinctures, topicals, and gummies. Its Cultured Foods and Lunar Fox cater to individuals seeking vegan, gluten-free, or flexitarian options for a nutritious and satisfying culinary experience. Its +PlusHLTH is a line of cannabinoid-free supplements delivering targeted formulations for optimized health, improved performance and increased vitality.

  • Revenue in USD (TTM)14.37m
  • Net income in USD-1.48m
  • Incorporated2013
  • Employees47.00
  • Location
    CV Sciences Inc9530 PADGETT STREET, SUITE 107SAN DIEGO 92126United StatesUSA
  • Fax+1 (619) 876-4321
  • Websitehttps://cvsciences.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.